View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Thomas Vranken
  • Thomas Vranken

Fagron FIRST LOOK: Deep-dive into Fagron's warning letter

Following a conference call with management and a readthrough of the warning letter regarding Fagron's Wichita site, our assessment confirms that the issues highlighted in the letter refer mainly to observations that were already known to and being addressed by Fagron since last summer. While the language used by the FDA in the letter is strong, we interpret this in a broader context of the regulator raising the bar on quality standards in the pharmaceutical compounding industry. Three topics we...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Fagron: FDA warning letter received for Wichita

Hilde Van Boxstael ... (+3)
  • Hilde Van Boxstael
  • Thomas Vranken
  • Wim Lewi
 PRESS RELEASE

Fagron updates on FDA communication regarding the June 2024 inspection...

Fagron updates on FDA communication regarding the June 2024 inspection at Wichita Regulated information – inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 23 Dec 2024 – 7AM CET Fagron updates on FDA communication regarding the June 2024 inspection at Wichita Following the FDA’s routine inspection at Fagron’s Wichita facility conducted in June 2024, the Company received a warning letter from the FDA (Warning Letter) on December 19, 2024. The Warning Letter requires Fagron to enhance processes for investigating discrepancies, and validations of future manufacturing ca...

 PRESS RELEASE

Fagron verschaft een update over de FDA-communicatie met betrekking to...

Fagron verschaft een update over de FDA-communicatie met betrekking tot de inspectie in Wichita in juni 2024   Gereglementeerde informatie – voorwetenschap Nazareth (België)/Rotterdam (Nederland), 23 december 2024 – 7:00 CET Fagron verschaft een update over de FDA-communicatie met betrekking tot de inspectie in Wichita in juni 2024 Na de routine-inspectie van de FDA van de vestiging in Wichita in juni 2024, ontving de Vennootschap op 19 december 2024 een waarschuwingsbrief van de FDA (Warning Letter). De waarschuwingsbrief verplicht Fagron om de processen voor het onderzoeken van afwi...

Guy Sips ... (+12)
  • Guy Sips
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Kristof Samoy
  • Lynn Hautekeete
  • Michiel Declercq
  • Sharad Kumar S.P
  • Thibault Leneeuw
  • Thomas Couvreur
  • Thomas Vranken
  • Wim Hoste
  • Wim Lewi

Dynamic Top Pick List How to start 2025?

On this Friday the 13th we select for you 13 stocks to start 2025 with a bang : ABN Amro, Ackermans & van Haaren, Bekaert, D'Ieteren, EVS, Fagron, Fugro, Gimv, Melexis, Shurgard, Sofina, WDP and Xior However, we maintain a defensive stance in our Benelux selection at the start of 2025.. The long anticipated interest rate cuts by central banks are expected to continue their decline into 2025 (see graph above). However, the Trump election victory in the US hits European stocks even before he tak...

 PRESS RELEASE

Disclosure of notification received from FMR LLC

Disclosure of notification received from FMR LLC Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 26 November 2024 – 6.45 PM CET Disclosure of notification received from FMR LLC Pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies, Fagron received a notification from FMR LLC. Notification by FMR LLC On 21 November 2024, Fagron received a notification that the shareholding of Fidelity Management & Research Company LLC, a controlled undertaking of FMR LLC, crossed the disclosure threshold of 3% upwards on 18 Nov...

 PRESS RELEASE

Openbaarmaking van kennisgeving ontvangen van FMR LLC

Openbaarmaking van kennisgeving ontvangen van FMR LLC Gereglementeerde informatie Nazareth (België)/Rotterdam (Nederland), 26 november 2024 – 18u45 CET Openbaarmaking van kennisgeving ontvangen van FMR LLC Fagron heeft een kennisgeving ontvangen op grond van de Belgische Wet van 2 mei 2007 op de openbaarmaking van belangrijke deelnemingen in beursgenoteerde vennootschappen van FMR LLC. Kennisgeving van FMR LLC Op 21 november 2024 heeft Fagron een kennisgeving ontvangen dat het aandeelhouderschap van Fidelity Management & Research Company LLC, een onderneming onder controle van FMR LLC,...

Guy Sips ... (+11)
  • Guy Sips
  • Jacob Mekhael
  • Kristof Samoy
  • Lynn Hautekeete
  • Michiel Declercq
  • Sharad Kumar S.P
  • Thibault Leneeuw
  • Thomas Couvreur
  • Thomas Vranken
  • Wim Hoste
  • Wim Lewi

Dynamic Top Pick List Update November 2024 – Adding Azelis – Removing ...

With 2 changes in our Dynamic Top Pick list (we add Azelis and we remove Solvay) we maintain a defensive stance on the market for 2H24. The long anticipated interest rate cuts by central banks have finally started. The Trump election victory in the US does not bode well for European stocks as he favours a protectionist course. Although industrial companies with a US base could actually benefit. Cleantech names with exposure to the US could also suffer (unless owned by E.Musk). We expect the US ...

Kristof Samoy ... (+3)
  • Kristof Samoy
  • Thomas Vranken
  • Wim Hoste
Thomas Vranken
  • Thomas Vranken

Fagron Model update: FY24 outlook

Following Fagron's 3Q24 update, we update our FY24 outlook to reach the upper end of the revenue guidance of € 850-870m. In the coming quarters and years, we expect sustained solid performance across business units, as the company continues to benefit from increased outsourcing of pharmaceutical compounding and its operational excellence initiatives. We reiterate our € 24 TP, reflecting 27% upside vs the current share price, hence reiterate our Buy rating.

Thomas Vranken
  • Thomas Vranken

Fagron FIRST LOOK: Conference call feedback

Following our earlier note on the 3Q24 results this morning (LINK), we share our additional takeaways from the conference call hosted by Fagron to discuss its performance.

Luis de Toledo Heras
  • Luis de Toledo Heras

ODDO BHF Small & MIDCAP MORNING NEWS - 10/10/2024

Burckhardt Compression is a leading global supplier of compression solutions with a unique product offering (full range of reciprocating compressor technologies and services). It targets profitable growth with a 2022-2027e sales CAGR of 7.7% and a 2022-2027e EBIT CAGR of 12.1%. These prospects seem adequately discounted at our TP of CHF 612 reflecting historical and peer multiples. We initiate the coverage with a Neutral rating. - ...

Luis de Toledo Heras
  • Luis de Toledo Heras

ODDO BHF Small & MIDCAP MORNING NEWS - 10/10/2024

Burckhardt Compression is a leading global supplier of compression solutions with a unique product offering (full range of reciprocating compressor technologies and services). It targets profitable growth with a 2022-2027e sales CAGR of 7.7% and a 2022-2027e EBIT CAGR of 12.1%. These prospects seem adequately discounted at our TP of CHF 612 reflecting historical and peer multiples. We initiate the coverage with a Neutral rating. - ...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Fagron: Solid 3Q24 sales beat, M&A back on agenda with 3 sizeable strategic acquisitions. PostNL: Parliamentary debate on Dutch postal market not supportive

Hilde Van Boxstael ... (+3)
  • Hilde Van Boxstael
  • Thomas Vranken
  • Wim Lewi
Robert Jan Vos ... (+2)
  • Robert Jan Vos
  • Usama Tariq

Fagron N.V. : Another strong quarter as results top expectations

>Fagron reported another strong set of results - Fagron reported a strong set of Q3 results where group sales for the quarter came at €214.5m, 12.1% higher year on year (yoy) and up 3% from company compiled consensus (css) and around 7% higher than our estimate of €201m. On a regional level, EMEA reported sales of €73.6m, up 11.2% yoy, 1% higher than consensus and 8.5% higher than AA-OB estimate of €68m. For Latin America, sales came at €44.1m, down 2.6% yoy, 5% above...

Thomas Vranken
  • Thomas Vranken

Fagron FIRST LOOK: 3Q24 beats expectations across the board

3Q24 results outperformed our and CSS expectations across all regions on the back of sustained high growth in N-Am's CS activities and strong CER performance in LatAm. The company reiterates its FY24 topline guidance of 11-14% y/y growth, hence we maintain our € 24 TP and Buy rating.

 PRESS RELEASE

Fagron rapporteert uitstekende resultaten in het derde kwartaal 2024 m...

Fagron rapporteert uitstekende resultaten in het derde kwartaal 2024 met een omzetgroei van 12,1% en bevestigt de vooruitzichten voor het volledige jaar 2024 Gereglementeerde informatie - voorwetenschapNazareth (België)/Rotterdam (Nederland), 10 oktober 2024 – 7u CET Fagron rapporteert uitstekende resultaten in het derde kwartaal 2024 met een omzetgroei van 12,1% en bevestigt de vooruitzichten voor het volledige jaar 2024 Fagron, de toonaangevende wereldspeler in farmaceutische bereidingen, publiceert vandaag haar kwartaalresultaten voor de periode eindigend op 30 september 2024. Kernpun...

 PRESS RELEASE

Disclosure of notification received from AOC Pharma S.à r.l.

Disclosure of notification received from AOC Pharma S.à r.l. Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 8 October 2024 – 9:00 PM CET Disclosure of notification received from AOC Pharma S.à r.l. Pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies, Fagron received a notification from AOC Pharma S.à r.l. Notification by AOC Pharma S.à r.l. On 3 October 2024, Fagron received a notification that changes took place in the chain of controlled undertakings through which the shares in Fagron NV are effectively h...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch